@article {SUGITA4059, author = {KAZUO SUGITA and KAZUYOSHI KAWAKAMI and TAKASHI YOKOKAWA and YUTARO MAE and WATARU TOYA and AKANE HAGINO and KENICHI SUZUKI and MITSUKUNI SUENAGA and NOBUYUKI MIZUNUMA and TOSHIHARU YAMAGUCHI and TOSHIHIRO HAMA}, title = {Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer}, volume = {35}, number = {7}, pages = {4059--4062}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Hypothyroidism is one of the side-effects caused by regorafenib. In the Japanese subset of the CORRECT study, hypothyroidism developed in 1.5\% of the patients, but was not grade 3 or higher in any patient. Regorafenib is an oral multi-kinase inhibitor that has the same mechanism of action as sunitinb. However, the reported incidence of sunitinb-related hypothyroidism varies widely, ranging from 16.0\% in clinical trials to 35.4\% in post-marketing surveillance studies. In general, symptoms of hypothyroidism include fatigue and dysphonia. Hyperthyroidism must, therefore, be appropriately managed in order to maintain patient quality of life and avoid a critical level of hypothyroidism. During the first cycle of treatment with regorafenib, the incidence of abnormal thyroid-stimulating hormone (TSH) elevation was 31.4\%. Our results suggest that thyroid function tests should be performed from day 1 of treatment with regorafenib. It would be prudent to consider routine monitoring of thyroid function in all patients who receive regorafenib and to recommend endocrinological consultation as necessary.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/7/4059}, eprint = {https://ar.iiarjournals.org/content/35/7/4059.full.pdf}, journal = {Anticancer Research} }